Can we develop a CSF biomarker panel that reliably distinguishes idiopathic normal pressure hydrocephalus (iNPH) from [Alzheimer's disease](/diseases/alzheimers-disease) patients with comorbid NPH pathology, when both present with similar triad symptoms (gait disturbance, cognitive impairment, urinary incontinence)? This is critical because NPH is potentially reversible with ventriculoperitoneal (VP) shunting, while AD is not — yet up to 50% of iNPH patients have co-existing AD pathology that limits shunt response.
Can we develop a CSF biomarker panel that reliably distinguishes idiopathic normal pressure hydrocephalus (iNPH) from [Alzheimer's disease](/diseases/alzheimers-disease) patients with comorbid NPH pathology, when both present with similar triad symptoms (gait disturbance, cognitive impairment, urinary incontinence)? This is critical because NPH is potentially reversible with ventriculoperitoneal (VP) shunting, while AD is not — yet up to 50% of iNPH patients have co-existing AD pathology that limits shunt response.
Gap Addressed
Current clinical criteria (Hakim-Hakim test, tap test, lumbar infusion test) for NPH diagnosis have 30-50% shunt response rate, with many patients failing to improve due to undiagnosed AD co-pathology[@tarnaris2021]. Conversely, AD patients with undiagnosed NPH component receive suboptimal care. No biomarker panel currently exists to:
Confirm NPH pathophysiology before shunting
Predict shunt responsiveness
Identify the AD co-pathology burden
Validation Protocol
Phase 1: Prospective CSF and Imaging Biomarker Discovery (Cohort: 120 patients with NPH triad symptoms)
Baseline characterization: Comprehensive clinical assessment (triad severity scoring, MDS-UPDRS for gait, MoCA for cognition)
The following diagram shows the key molecular relationships involving CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Concomitant NPH discovered through SciDEX knowledge graph analysis: